466 related articles for article (PubMed ID: 24501221)
41. CLLonal selection: survival of the fittest?
Dearden C
Blood; 2014 Apr; 123(14):2130-1. PubMed ID: 24700713
[TBL] [Abstract][Full Text] [Related]
42. Detection and Functional Analysis of TP53 Mutations in CLL.
Pavlova S; Smardova J; Tom N; Trbusek M
Methods Mol Biol; 2019; 1881():63-81. PubMed ID: 30350198
[TBL] [Abstract][Full Text] [Related]
43. Insight into del17p low-frequency subclones in chronic lymphocytic leukaemia (CLL): data from the Australasian Leukaemia and Lymphoma Group (ALLG)/CLL Australian Research Consortium (CLLARC) CLL5 trial.
Do C; Best OG; Thurgood L; Hotinski A; Apostolou S; Mulligan SP; Lower K; Kuss B
Br J Haematol; 2021 May; 193(3):556-560. PubMed ID: 33851417
[TBL] [Abstract][Full Text] [Related]
44. Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial.
Blakemore SJ; Clifford R; Parker H; Antoniou P; Stec-Dziedzic E; Larrayoz M; Davis Z; Kadalyayil L; Colins A; Robbe P; Vavoulis D; Forster J; Carr L; Morilla R; Else M; Bryant D; McCarthy H; Walewska RJ; Steele AJ; Chan J; Speight G; Stankovic T; Cragg MS; Catovsky D; Oscier DG; Rose-Zerilli MJJ; Schuh A; Strefford JC
Leukemia; 2020 Jul; 34(7):1760-1774. PubMed ID: 32015491
[TBL] [Abstract][Full Text] [Related]
45. p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL.
Lee HJ; Gallardo M; Ma H; Zhang X; Larsson CA; Mejia A; Hornbaker MJ; Qi Y; Su X; Pageon LR; Quintas-Cardama A; Post SM
Blood Cancer J; 2016 Jun; 6(6):e434. PubMed ID: 27284738
[TBL] [Abstract][Full Text] [Related]
46. Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosis.
Greipp PT; Smoley SA; Viswanatha DS; Frederick LS; Rabe KG; Sharma RG; Slager SL; Van Dyke DL; Shanafelt TD; Tschumper RC; Zent CS
Br J Haematol; 2013 Nov; 163(3):326-33. PubMed ID: 24032430
[TBL] [Abstract][Full Text] [Related]
47. TP53 mutation and survival in chronic lymphocytic leukemia.
Zenz T; Eichhorst B; Busch R; Denzel T; Häbe S; Winkler D; Bühler A; Edelmann J; Bergmann M; Hopfinger G; Hensel M; Hallek M; Döhner H; Stilgenbauer S
J Clin Oncol; 2010 Oct; 28(29):4473-9. PubMed ID: 20697090
[TBL] [Abstract][Full Text] [Related]
48. Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia.
Leeksma AC; Taylor J; Wu B; Gardner JR; He J; Nahas M; Gonen M; Alemayehu WG; Te Raa D; Walther T; Hüllein J; Dietrich S; Claus R; de Boer F; de Heer K; Dubois J; Dampmann M; Dürig J; van Oers MHJ; Geisler CH; Eldering E; Levine RL; Miller V; Mughal T; Lamanna N; Frattini MG; Heaney ML; Zelenetz A; Zenz T; Abdel-Wahab O; Kater AP
Leukemia; 2019 Feb; 33(2):390-402. PubMed ID: 30038380
[TBL] [Abstract][Full Text] [Related]
49. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype.
Dicker F; Herholz H; Schnittger S; Nakao A; Patten N; Wu L; Kern W; Haferlach T; Haferlach C
Leukemia; 2009 Jan; 23(1):117-24. PubMed ID: 18843282
[TBL] [Abstract][Full Text] [Related]
50. Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations.
Blanco G; Puiggros A; Baliakas P; Athanasiadou A; García-Malo M; Collado R; Xochelli A; Rodríguez-Rivera M; Ortega M; Calasanz MJ; Luño E; Vargas M; Grau J; Martínez-Laperche C; Valiente A; Cervera J; Anagnostopoulos A; Gimeno E; Abella E; Stalika E; Hernández-Rivas JM; Ortuño FJ; Robles D; Ferrer A; Ivars D; González M; Bosch F; Abrisqueta P; Stamatopoulos K; Espinet B
Oncotarget; 2016 Dec; 7(49):80916-80924. PubMed ID: 27821812
[TBL] [Abstract][Full Text] [Related]
51. Clinical impact of small subclones harboring NOTCH1, SF3B1 or BIRC3 mutations in chronic lymphocytic leukemia.
Rasi S; Khiabanian H; Ciardullo C; Terzi-di-Bergamo L; Monti S; Spina V; Bruscaggin A; Cerri M; Deambrogi C; Martuscelli L; Biasi A; Spaccarotella E; De Paoli L; Gattei V; Foà R; Rabadan R; Gaidano G; Rossi D
Haematologica; 2016 Apr; 101(4):e135-8. PubMed ID: 26819056
[No Abstract] [Full Text] [Related]
52. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia.
Pospisilova S; Gonzalez D; Malcikova J; Trbusek M; Rossi D; Kater AP; Cymbalista F; Eichhorst B; Hallek M; Döhner H; Hillmen P; van Oers M; Gribben J; Ghia P; Montserrat E; Stilgenbauer S; Zenz T;
Leukemia; 2012 Jul; 26(7):1458-61. PubMed ID: 22297721
[TBL] [Abstract][Full Text] [Related]
53. Relevance of TP53 for CLL diagnostics.
Catherwood MA; Gonzalez D; Donaldson D; Clifford R; Mills K; Thornton P
J Clin Pathol; 2019 May; 72(5):343-346. PubMed ID: 30712002
[No Abstract] [Full Text] [Related]
54. Chronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype, and TP53 disruption.
Garces S; Khoury JD; Kanagal-Shamanna R; Salem A; Wang SA; Ok CY; Hu S; Patel KP; Routbort MJ; Luthra R; Tang G; Schlette EJ; Bueso-Ramos CE; Medeiros LJ; Loghavi S
Hum Pathol; 2018 Dec; 82():215-231. PubMed ID: 30086334
[TBL] [Abstract][Full Text] [Related]
55. Clonal evolution, genomic drivers, and effects of therapy in chronic lymphocytic leukemia.
Ouillette P; Saiya-Cork K; Seymour E; Li C; Shedden K; Malek SN
Clin Cancer Res; 2013 Jun; 19(11):2893-904. PubMed ID: 23620403
[TBL] [Abstract][Full Text] [Related]
56. Impact of Low-Burden
Lazarian G; Cymbalista F; Baran-Marszak F
Front Oncol; 2022; 12():841630. PubMed ID: 35211418
[TBL] [Abstract][Full Text] [Related]
57. Comprehensive Analysis of Disease-Related Genes in Chronic Lymphocytic Leukemia by Multiplex PCR-Based Next Generation Sequencing.
Vollbrecht C; Mairinger FD; Koitzsch U; Peifer M; Koenig K; Heukamp LC; Crispatzu G; Wilden L; Kreuzer KA; Hallek M; Odenthal M; Herling CD; Buettner R
PLoS One; 2015; 10(6):e0129544. PubMed ID: 26053404
[TBL] [Abstract][Full Text] [Related]
58. Distinct in vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximab.
Sebejova L; Borsky M; Jaskova Z; Potesil D; Navrkalova V; Malcikova J; Sramek M; Doubek M; Loja T; Pospisilova S; Mayer J; Trbusek M
Exp Hematol; 2014 Oct; 42(10):867-74.e1. PubMed ID: 24970561
[TBL] [Abstract][Full Text] [Related]
59. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness.
Rossi D; Bruscaggin A; Spina V; Rasi S; Khiabanian H; Messina M; Fangazio M; Vaisitti T; Monti S; Chiaretti S; Guarini A; Del Giudice I; Cerri M; Cresta S; Deambrogi C; Gargiulo E; Gattei V; Forconi F; Bertoni F; Deaglio S; Rabadan R; Pasqualucci L; Foà R; Dalla-Favera R; Gaidano G
Blood; 2011 Dec; 118(26):6904-8. PubMed ID: 22039264
[TBL] [Abstract][Full Text] [Related]
60. Gene mutations in chronic lymphocytic leukemia.
Amin NA; Malek SN
Semin Oncol; 2016 Apr; 43(2):215-21. PubMed ID: 27040699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
